ADAC technology platform - the next step in personalized immunotherapy

Precision therapy through affinity-based antibody conjugation

Latest News

News

February 4, 2025

Per Norlén joins Strike Pharma as new CEO

Read More
News

September 10, 2024

Strike Pharma presents updates at CICON24

Read More
News

July 4, 2024

Strike Pharma granted patent to protect core technology

Read More
News

July 4, 2024

Strike Pharma receives funding from BIO-X Accelerate program

Read More
Event

September 24, 2023

Strike Pharma presents further developments at CICON23

Read More
News

May 16, 2023

Strike Pharma and FyoniBio conclude successful cell line development of Strike’s bi-specific antibody and clinical lead candidate

Read More
Event

April 18, 2023

Strike Pharma presents latest developments at AACR 2023

Read More
News

December 5, 2022

Funds awarded to study ADAC™ technology in depth

Read More
News

November 3, 2022

Strike Pharma continues expansion of management team

Read More
News

October 20, 2022

Strike Pharma and FyoniBio sign Master Service Agreement

Read More
News

August 30, 2022

Strike Pharma’s Chief Scientific Officer receives BiotechBuilders Award 2022

Read More
News

June 20, 2022

Strike Pharma strengthens Board of Directors

Read More
See more News

Latest Events

See more Events